ArticleEndocrine2025
Contribution of neck ultrasonography to patient management in patients with differentiated thyroid carcinoma with excellent response to therapy.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of patients with low-risk differentiated thyroid cancer with an excellent response to initial therapy.European thyroid journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the contribution of intense neck ultrasonography (US) follow-up in the clinical management of differentiated thyroid carcinoma (DTC) patients with the American Thyroid Association (ATA) low-intermediate-risk of recurrence and an excellent response after total thyroidectomy and radioiodine therapy. MATERIALS AND
methodsMedical records of patients who underwent serial follow-up neck US examinations between 1996 and 2022 were analyzed retrospectively. The utility of serial US examinations in detecting structural recurrence was assessed in all patients and different subgroups-categorized per the initial risk of recurrence and stimulated thyroglobulin (sTg) level at 1-year response assessment.
resultsAmong 2823 US examinations in 296 patients, 2 (0.1%) were categorized as true-positive, 2670 (94.6%) as true-negative, and 151 (5.3%) as false-positive, whereas no false-negative results were observed. Thus, sensitivity, specificity, positive predictive value (PPV), negative predictive value, and accuracy [confidence interval] in all patients were 100% [34.2-100%], 94.7% [93.8-95.4%], 1.3% [0.36-4.6%], 100% [99.9-100%], and 94.7% [93.8-95.4%], respectively. Non-significant higher PPVs were calculated in intermediate-risk patients and patients having sTg ≥0.1 ng/mL, while slightly lower specificity and accuracy were demonstrated in the former group. No recurrence was identified in patients with a low risk of recurrence and those having sTg <0.1 ng/mL.
conclusionFrequent US examination yields remarkably low PPVs in identifying recurrences in ATA low-intermediate-risk patients with DTC and attaining excellent response after total thyroidectomy and radioiodine ablation. Therefore, US surveillance protocol should be individualized per the initial risk of recurrence and Tg levels at response assessment.
Indexed as
Identifiers
39738889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.